March 10, 2026
Applications Open for Health Innovation Program with Novartis Türkiye

Innovation in healthcare requires bold ideas, and the entrepreneurs ready to deliver them. That’s why Novartis Türkiye and Tenity are launching the Health Innovation Program, bringing together Healthtech and Fintech startups that are reshaping the way patients access care and engage with healthcare systems.

Why Health Innovation Program 2026 matters

Health Innovation Program 2026 is designed to connect visionary founders with Novartis Türkiye experts to tackle some of the most pressing needs in healthcare today. The program focuses on solutions that:

  • Improve healthcare engagement
  • Increase access to innovative medicine
  • Create sustainable, affordable and equitable innovative solutions at the intersection of HealthTech and FinTech for patients.

By combining Novartis Türkiye’s innovation legacy in healthcare with Tenity’s strength in startup acceleration, the program offers a unique platform for entrepreneurs to validate their solutions and explore real-world impact.

Istanbul stands at the crossroads of regions, cultures, and markets — a natural hub for innovation. Hosting the Health Innovation Program here underlines its role as a vibrant meeting point for Healthtech and Fintech ecosystems, where ideas can scale across both regional and global markets.

What’s in it for startups

Ten startups will be selected to pitch their solutions live at the Novartis Health Innovation Program on 11 June 2026 in Ankara. In front of Novartis Türkiye experts, world-leading investors, industry leaders and public authorities they will present how their solutions can reimagine access to innovative medicines. The top three startups will move forward with:

  • Mentorship from Novartis experts
  • The chance to explore partnership opportunities
  • Access to a strong innovation network in healthcare and financial services

Application deadline: 10 April 2026

Challenge Day: 11 June 2026 (Ankara)

The call is intended solely for applications submitted within the scope of the Program and must not be used for any other purpose. Any use for purposes other than those specified shall not be considered binding for Novartis Türkiye.